These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10639373)

  • 1. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
    Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Feb; 44(2):414-7. PubMed ID: 10639373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK.
    Johnson AP; Henwood CJ; Tysall L; Warner M
    Int J Antimicrob Agents; 2001 Jul; 18(1):73-6. PubMed ID: 11463530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
    Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.
    Matic V; Kosowska K; Bozdogan B; Kelly LM; Smith K; Ednie LM; Lin G; Credito KL; Clark CL; McGhee P; Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4103-12. PubMed ID: 15504828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
    Morosini MI; Cantón R; Loza E; Negri MC; Galán JC; Almaraz F; Baquero F
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2427-31. PubMed ID: 11502509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 1998 Apr; 42(4):945-6. PubMed ID: 9559816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
    Johnson CN; Benjamin WH; Gray BM; Crain MC; Edwards KM; Waites KB
    Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.
    Credito KL; Ednie LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2027-31. PubMed ID: 10428930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae.
    Johnston NJ; De Azavedo JC; Kellner JD; Low DE
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2425-6. PubMed ID: 9736575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P; Juvin ME; Tassin S; Bryskier A; Schito GC; Drugeon HB
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics.
    Nishijima T; Saito Y; Aoki A; Toriya M; Toyonaga Y; Fujii R
    J Antimicrob Chemother; 1999 May; 43(5):637-43. PubMed ID: 10382884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
    Pankuch GA; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):624-30. PubMed ID: 9517943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
    J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of six macrolides, clindamycin and tetracycline on Streptococcus pneumoniae with different penicillin susceptibilities.
    Poulsen RL; Knudsen JD; Petersen MB; Fuursted K; Espersen F; Frimodt-Møller N
    APMIS; 1996 Mar; 104(3):227-33. PubMed ID: 8611198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary.
    Zhanel GG; Johanson C; Laing N; Hisanaga T; Wierzbowski A; Hoban DJ
    Antimicrob Agents Chemother; 2005 May; 49(5):1943-8. PubMed ID: 15855517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of the new ketolide telithromycin and other antibiotics against Streptococcus pneumoniae in Belgium.
    Verhaegen J; Verbist L
    Acta Clin Belg; 2001; 56(6):349-53. PubMed ID: 11881319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study.
    Mazzariol A; Koncan R; Bahar G; Cornaglia G
    J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.